Healthcare Policy

Insulin pricing in flux as major pharma players take action

As the three main US pharmaceutical insulin suppliers, Novo Nordisk, Sanofi and Eli Lilly, have announced major price reductions, and…

MHRA revamps UK clinical trial regulation with the promise of faster timelines

This week, the Medicines and Healthcare products Regulatory Agency (MHRA) is introducing major changes to clinical trial regulation in the…

Legal challenges put off label use of gender affirming care drugs in jeopardy

Earlier this week, the Florida Senate advanced a bill to restrict gender-affirming care for transgender minors. The bill is one…

ESG permeates pharmaceutical pricing strategy

As ESG criteria gains greater traction across the pharmaceutical landscape, the push for pricing sustainability is growing more forceful. To…

Canada’s PMPRB reform delays add uncertainty

The government of Canada has once again decided to delay the implementation of the major drug pricing reforms that were…

Industry hopes dashed after EU compromises to squeeze through cross border HTA agreement

The innovative pharmaceutical industry has emerged shaken following last week's compromise-driven agreement on joint scientific health technology assessments in the…

Vaccine hesitancy boosts risks from vaccine nationalism

There has been a lot of talk about vaccine nationalism - the practice of countries hoarding limited vaccine supplies - and the…

Biden administration scores first legislative win for pharmaceutical pricing reform

With the passage of The American Rescue Plan of 2021, President Joe Biden has marked the first legislative achievement of…

AMNOG ten years on: Impact on the Europe top 5 price level hierarchy

Ten years after implementation of the AMNOG reform in Germany, the price level hierarchy among the Europe Top 5 markets…

Pharma and healthcare top 10: What to expect in 2021 and beyond

After the extreme unpredictability of 2020, the world is now looking at 2021 with the hope to return to a…